M&A
confidence high
sentiment positive
materiality 0.60
Azenta takes exclusive Elegen gene-synthesis license and buys SynPlexity to expand GENEWIZ
Azenta, Inc.
- Exclusive, royalty-free license to Elegen's gene synthesis and cell-free cloning patents and know-how; initial five-year term, extendable by mutual agreement.
- Azenta can exercise an option 12-18 months after signing, paying $25M, to convert to an irrevocable, perpetual, exclusive, royalty-free license.
- Aggregate capital deployment of $32M-$71M, depending on future equipment purchases and whether Azenta exercises the perpetual-license option.
- Acquired all outstanding stock of SynPlexity Inc. under an Oct. 28, 2026 Stock Purchase Agreement that closed concurrently; purchase price not disclosed.
- SynPlexity's pooled gene assembly yields thousands of full-length gene variants per library; technology to be folded into the GENEWIZ synthesis portfolio.